NCT02798211 · Interventional trial
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Overall registry status Completed
Phase 4
Conditions Psoriatic Arthritis
Delaware Valley sites
- Novartis Investigative Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory